Mereo BioPharma Group plc
MREODrugs in Pipeline
6
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 11, 2026
7dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
MREO Earnings Report
EPS Est: $-0.01 | FQ end 2026-06
How MREO's past catalysts played out
BCT197
Pulmonary Disease, Chronic Obstructive
Prednisone
Chronic Obstructive Pulmonary Disease
Alvelestat oral tablet - dose 1
Alpha 1-Antitrypsin Deficiency
Etigilimab
Solid Tumor, Adult
BGS649
Hypogonadotropic Hypogonadism
Active treatment with a high dose of BGS649
Endometriosis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
BCT197 | Phase 2 | Pulmonary Disease, Chronic Obstructive | - | - |
Prednisone | Phase 2 | Chronic Obstructive Pulmonary Disease | - | - |
Alvelestat oral tablet - dose 1 | Phase 2 | Alpha 1-Antitrypsin Deficiency | - | - |
Etigilimab | Phase 2 | Solid Tumor, Adult | - | - |
BGS649 | Phase 2 | Hypogonadotropic Hypogonadism | - | - |
Active treatment with a high dose of BGS649 | Phase 2 | Endometriosis | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Mereo BioPharma Group plc's drug pipeline?→
CatalystAlert tracks 6 drug candidates in Mereo BioPharma Group plc's (MREO) pipeline across Phase 2. Its lead program is BCT197 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Mereo BioPharma Group plc's next FDA catalyst?→
Mereo BioPharma Group plc's (MREO) next tracked catalyst is a Earnings expected August 11, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track MREO biotech catalysts?→
Add MREO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Mereo BioPharma Group plc's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.